

HAB HIV Performance Measures: ADAP: AIDS Drug Assistance Program

Performance Measure: ADAP: Eligibility Recertification	
Percentage of ADAP enrollees ¹ who are reviewed for continued ADAP eligibility ² two or more times in the measurement year.	
Numerator:	Number of ADAP enrollees who are reviewed for continued ADAP eligibility ² at least two or more times which are at least 150 days apart in the measurement year.
Denominator:	Number of clients enrolled in ADAP ³ in the measurement year.
Patient Exclusions:	<ol style="list-style-type: none"> 1. Clients approved for new ADAP enrollment in the measurement year. 2. Clients terminated from ADAP in the first 180 days of the measurement year.
Data Element:	<ol style="list-style-type: none"> 1. Was the client enrolled in ADAP during the measurement year? (Y/N) <ol style="list-style-type: none"> a. If yes, was the client reviewed for continued ADAP eligibility¹ two or more times at least 150 days apart during the measurement year? (Y/N) <ol style="list-style-type: none"> i. If yes, list the dates of review.
Data Sources:	<ul style="list-style-type: none"> • AIDS Drug Assistance Program Quarterly Data Report, Section 2: Annual Submission
National Goals, Targets, or Benchmarks for Comparison:	Part B Collaborative ⁴ : 92%
Basis for Selection:	
The Ryan White HIV Treatment Modernization Act of 2006 (P.L. 109-415) ⁵ requires that the Ryan White HIV/AIDS Program be the payor of last resort. HAB Policy 07-03 specifies that “grantees must be capable of providing the HAB with documentation related to the use of funds as payor of last resort and the coordination of such funds with other local, State and Federal funds.” ⁶	
US Public Health Service Guidelines:	
This measure addresses the intent of HHS Treatment Guidelines for the use of antiretroviral agents and the prevention and treatment of opportunistic infections in HIV infected individuals. ⁷⁻¹¹	
References/Notes:	
<p>¹ Includes all individuals, regardless of age.</p> <p>² “Review for continued ADAP enrollment” (recertification) is a process for “confirming that a client receiving ADAP-funded services is still eligible to receive those services.” Verification of ADAP eligibility includes verification of third party payor sources, such as Medicaid and Medicare. [Source: “Instructions for Completing The Drug Assistance Program Quarterly Data Report”. Available at ftp://ftp.hrsa.gov/hab/ADAP%20Instructions_Final%20Feb%202022_08_.pdf, page 20. Accessed July 17, 2009.]</p> <p>³ Clients enrolled in ADAP: Refers to “the total number of individuals who are enrolled or certified as eligible to receive medications in...ADAP, regardless of whether they used ADAP services. [Source: “Instructions for Completing The Drug Assistance Program Quarterly Data Report”. Available at</p>	

HAB HIV Performance Measures: ADAP: AIDS Drug Assistance Program

Performance Measure: ADAP: Eligibility Recertification

ftp://ftp.hrsa.gov/hab/ADAP%20Instructions_Final%20Feb%202022_08_.pdf. Accessed July 17, 2009.]

⁴ Part B Collaborative measure reads: “Percent of ADAP enrollees recertified for ADAP eligibility criteria at least annually”.

⁵The Ryan White HIV Treatment Modernization Act of 2006 (P.L. 109-415), Section 202(a).

⁶HRSA/HAB, Policy Notice-07-03, “The Use of Ryan White HIV/AIDS Program, Part B (formerly Title II), AIDS Drug Assistance Program (ADAP) Funds for Access, Adherence and Monitoring Services”, September 2007.

⁷ Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161.. Available at <http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>. Accessed December 7, 2009.

⁸ Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. February 23, 2009; pp 47. Available at <http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf>. Accessed September 9, 2009.

⁹ Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. April 29, 2009; pp 1-90. Available at <http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf>. Accessed September 9, 2009.

¹⁰ Centers for Disease Control and Prevention. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. MMWR 2009;58(No. RR-4): 1-216. Available at: <http://www.cdc.gov/mmwr/pdf/rr/rr5804.pdf>. Accessed September 9, 2009.

¹¹ Centers for Disease Control and Prevention. Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children. MMWR 2009;58(No. RR-11): 1-176. Available at: http://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf. Accessed September 9, 2009.